Company Overview and News
BENGALURU (June 20): Australian shares closed at their highest level in nearly 10½ years, driven by a rally in banks, but a fall for Telstra after it flagged major job cuts and asset sales in a "strategic reset" capped Wednesday's gains.
WBC CMXHF WBC TLS WEBNF CHEOF WBK TTRAF TLSYY CHEOY SML
CANBERRA, Australia (AP) — Telstra Corp., Australia's largest telecommunications company, has announced plans to ax 8,000 jobs — one in four employees — over three years in a bid to save 1 billion Australian dollars ($740 million).
TLS TTRAF TLSYY
Telstra Ltd (ASX:TLS) is by far the most active stock on the market today, trading 74 million shares by noon, with the valuation wiped down by 5.5% to $2.75.
AGO TLS TLS ATLGF AGODY TTRAF TLSYY
AUSTRALIAN telecommunications company Telstra Corp. Ltd. said it will not join the bidding process for the “third” major telecommunications player in the Philippines.
SMCP1 GTMEY GLOPP TTRAF TLSYY SMGBY SMGBF GLO SMC2B SMC2A SMC SMC2D SMC2C TLS SMC2F SMC2E GTMEF GLOPA
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
GJV FOX NWS NWSA TLS TTRAF TLSYY FOXA
Good afternoon. My name is Sarah and I will be your conference operator today. At this time, I would like to welcome everyone to the TiVo 2018 First Quarter Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
TLS TTRAF TLSYY TIVO
C88 FINANCIAL Technologies Pte Ltd., owner and operator of website eCompareMo, is using artificial intelligence and data technologies to serve its customers as it looks to launch products to help Filipino consumers looking to tap financial services.
TLS TTRAF TLSYY
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET